VBI Vaccines to Present at the Jefferies Healthcare Conference
(firmenpresse) - CAMBRIDGE, MASSACHUSETTS -- (Marketwired) -- 05/27/16 -- VBI Vaccines Inc. (NASDAQ: VBIV)(TSX: VBV) ("VBI") is scheduled to present at the Jefferies 2016 Healthcare Conference on Friday, June 10 at 2:30 PM ET. The event is being held at the Grand Hyatt New York in New York City.
During the presentation, Jeff Baxter, VBI''s President and CEO, will provide an and its , and will summarize recent developments in the company''s . Mr. Baxter will also discuss VBI''s recently completed merger with SciVac Therapeutics and ™, a third-generation licensed hepatitis B vaccine.
At the time of the presentation, a live audio webcast will be available at:
VBI recommends registering for the webcast at least ten minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived for 90 days following the event.
The Jefferies Healthcare Conference features an extensive range of public and private healthcare companies across the biopharmaceuticals, life sciences, and healthcare services sectors. For additional information, or to schedule a one-on-one meeting with VBI management, please contact .
Event Details
About VBI Vaccines Inc.
VBI Vaccines Inc. ("VBI") is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI''s first marketed product is Sci-B-Vac™, a hepatitis B ("HBV") vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI''s eVLP Platform technology allows for the development of enveloped ("e") virus-like particle ("VLP") vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus ("CMV") and glioblastoma multiforme ("GBM"). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.
Cautionary Statement on Forward-looking Information
Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collectively, "forward-looking statements") that may not be based on historical fact, but instead relate to future events, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. All statements other than statements of historical fact included in this release are forward-looking statements.
Such forward-looking statements are based on a number of assumptions, including assumptions regarding the successful development and/or commercialization of the company''s products, including the receipt of necessary regulatory approvals; general economic conditions; competitive conditions; and changes in applicable laws, rules and regulations.
VBI cautions the reader that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release and VBI has made assumptions and estimates based on or related to many of these factors.
Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on the company''s current expectations, and the company undertakes no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.
Contacts:
VBI Contact
Perri Maduri
Communications Executive
(617) 830-3031 x124
VBI Investor Contact
Nell Beattie
Director, Corporate Development and Investor Relations
(617) 830-3031 x128
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 27.05.2016 - 06:30 Uhr
Sprache: Deutsch
News-ID 1437927
Anzahl Zeichen: 2326
contact information:
Contact person:
Town:
CAMBRIDGE, MASSACHUSETTS
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 264 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"VBI Vaccines to Present at the Jefferies Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
VBI Vaccines Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
